HLA-DRB1 antibody

Catalog No. ABIN2665043

Product Details anti-HLA-DRB1 Antibody

Target: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This HLA-DRB1 antibody is un-conjugated

Application: Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)

Purification: The antibody was purified by affinity chromatography.

Clone: NFLD-D2

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for HLA-DRB1

Target: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Alternative Name: HLA-DRB1 (HLA-DRB1 Products)

Synonyms: MGC108235 antibody, DRB1 antibody, DRw10 antibody, HLA-DR1B antibody, HLA-DRB antibody, SS1 antibody, major histocompatibility complex, class II, DR beta 1 antibody, hla-drb1 antibody, HLA-DRB1 antibody

Background: HLA-DRB1, a HLA class II beta chain paralog, is a heterodimer membrane anchored α (DRA) and β chain (DRB). It plays an imporant role in extracellular protein-derived peptide presentation. It is expressed by antigen presenting cells (APC) such as B cells, dendritic cells, and macrophages. The β chain (composed of β1 and β2) is 26-28 kD and contains polymorphisms allowing for variability in peptide binding specificities. DRB1 is expressed by all individuals and its expression is five fold higher than DRB chains 3, 4, or 5. The peptide binding groove can accommodate peptides 10-30 residues long. Thirty-three different sub-types of HLA-DRB1*04 have been described. Of these, HLA-DRB1*04 is associated with an increased incidence of rheumatoid arthritis and is present on a subset of DRB1 Molecules.

Pathways: TCR Signaling, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, CXCR4-mediated Signaling Events, Cancer Immune Checkpoints